Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

REACTIVITY SENSITIVITY MW (kDa) SOURCE
95 Rabbit

Product Usage Information

Application Dilutions
Western Blotting 1:1000
Immunofluorescence 1:100

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

PLK4 Antibody detects endogenous levels of total PLK4 protein.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Cys458 of human PLK4. Antibodies were purified by peptide affinity chromatography.

At least four distinct polo-like kinases exist in mammalian cells: PLK1, PLK2, PLK3, and PLK4/SAK (1). PLK1 apparently plays many roles during mitosis, particularly in regulating mitotic entry and exit. The mitosis promoting factor (MPF), cdc2/cyclin B1, is activated by dephosphorylation of cdc2 (Thr14/Tyr15) by cdc25C. PLK1 phosphorylates cdc25C at Ser198 and cyclin B1 at Ser133 causing translocation of these proteins from the cytoplasm to the nucleus (2-5). PLK1 phosphorylation of Myt1 at Ser426 and Thr495 has been proposed to inactivate Myt1, one of the kinases known to phosphorylate cdc2 at Thr14/Tyr15 (6). Polo-like kinases also phosphorylate the cohesin subunit SCC1, causing cohesin displacement from chromosome arms that allow for proper cohesin localization to centromeres (7). Mitotic exit requires activation of the anaphase promoting complex (APC) (8), a ubiquitin ligase responsible for removal of cohesin at centromeres, and degradation of securin, cyclin A, cyclin B1, Aurora A, and cdc20 (9). PLK1 phosphorylation of the APC subunits Apc1, cdc16, and cdc27 has been demonstrated in vitro and has been proposed as a mechanism by which mitotic exit is regulated (10,11).

Substitution of Thr210 with Asp has been reported to elevate PLK1 kinase activity and delay/arrest cells in mitosis, while a Ser137Asp substitution leads to S-phase arrest (12). In addition, while DNA damage has been found to inhibit PLK1 kinase activity, the Thr210Asp mutant is resistant to this inhibition (13). PLK1 has been reported to be phosphorylated in vivo at Ser137 and Thr210 in mitosis; DNA damage prevents phosphorylation at these sites (14).


PLK4/SAK is transcriptionally repressed by p53 and may contribute to p53-mediated apoptosis (12). PLK4 has also been identified as a key regulator of centriole duplication (13-15).


1.  Nigg, E.A. (1998) Curr. Opin. Cell Biol. 10, 776-783.

2.  Toyoshima-Morimoto, F. et al. (2002) EMBO Rep. 3, 341-348.

3.  Toyoshima-Morimoto, F. et al. (2001) Nature 410, 215-220.

4.  Peter, M. et al. (2002) EMBO Rep. 3, 551-556.

5.  Jackman, M. et al. (2003) Nat. Cell Biol. 5, 143-148.

6.  Nakajima, H. et al. (2003) J. Biol. Chem. 278, 25277-25280.

7.  Sumara, I. et al. (2002) Mol. Cell 9, 515-525.

8.  Hauf, S. et al. (2001) Science 293, 1320-1323.

9.  Peters, J.M. (1999) Exp. Cell Res. 248, 339-349.

10.  Kraft, C. et al. (2003) EMBO J. 22, 6598-6609.

11.  Kotani, S. et al. (1998) Mol. Cell 1, 371-380.

12.  Jang, Y.J. et al. (2002) J Biol Chem 277, 44115-20.

13.  Smits, V.A. et al. (2000) Nat Cell Biol 2, 672-6.

14.  Tsvetkov, L. and Stern, D.F. (2005) Cell Cycle 4, 166-71.

15.  Li, J. et al. (2005) Neoplasia 7, 312-323.

16.  Habedanck, R. et al. (2005) Nat. Cell Biol. 7, 1140-1146.

17.  Ko, M.A. et al. (2005) Nat. Genet. 37, 883-888.

18.  Bettencourt-Dias, M. et al. (2005) Curr. Biol. 15, 2199-2207.


Entrez-Gene Id 10733
Swiss-Prot Acc. O00444

Product Specific References

Raab, M. et al. (2011) Nat Commun 2, 395.


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Alexa Fluor® is a registered trademark of Life Technologies Corporation.
DRAQ5® is a registered trademark of Biostatus Limited.